Results 311 to 320 of about 1,006,225 (339)

Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival

Journal of Surgical Oncology, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is effective in select patients with peritoneal carcinomatosis (PC). Signet ring cell (SRC) pathology is associated with poor prognosis.
D. Solomon, Natasha DeNicola, D. Feingold, Peter H. Liu, Samantha N. Aycart, B. Golas, U. Sarpel, D. Labow, D. Magge   +8 more
semanticscholar   +1 more source

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on

Cancer, 2019
Patients with advanced epithelial ovarian cancer have a high incidence of peritoneal disease recurrence despite maximal efforts to surgically remove all visible tumor plus intravenous chemotherapy.
S. Koole, W. V. van Driel, G. Sonke
semanticscholar   +1 more source

The use of intraperitoneal chemotherapy for gastric malignancies

Expert Review of Anticancer Therapy, 2019
Introduction: Gastric cancer is the fourth/fifth most common malignancy worldwide, with only a quarter of patients achieving a 5-year survival rate. It has been estimated that 15–50% or more of patients have peritoneal disease upon surgical exploration ...
A. Macrì, F. Morabito
semanticscholar   +1 more source

Principles of Intraperitoneal Chemotherapy

2010
Despite the completion and publication of the results of three well-designed and conducted phase III randomized trials that revealed the superiority of intraperitoneal, compared to intravenous cisplatin-based chemotherapy employed as primary chemotherapy of small-volume residual advanced ovarian cancer [1–3], there appears to be limited use of this ...
openaire   +2 more sources

Intraperitoneal regional chemotherapy with mitroxantrone

1996
Pharmacokinetic considerations and tests with cell lines and individual cell suspensions from metastatic human solid tumor biopsies suggested testing the efficacy of mitoxantrone (NOV) in intraperitoneal regional chemotherapy (IPRC). Twenty-seven patients with intraperitoneal metastatic disease of various solid tumors received cyclic IPRC with NOV for ...
Ludger Staib, W. Böhm, G. Hepp, H. G. Beger, Urwe Butzer, Karl H. Link   +5 more
openaire   +3 more sources

Adjuvant Intraperitoneal Chemotherapy: A Review

2007
The rationale for adding perioperative chemotherapy to the management of gastrointestinal and ovarian cancer was developed by Cunliffe and Sugarbaker in 1989. They based the rationale for this novel approach on the patterns of recurrence of both gastrointestinal and ovarian cancer [1].
openaire   +3 more sources

Intraperitoneal Chemotherapy

Annals of Internal Medicine, 1984
R F, Ozols, C E, Myers, R C, Young
openaire   +2 more sources

Selection of Chemotherapy in Hyperthermic Intraperitoneal Chemotherapy

2017
The peritoneum consists of a layer of mesothelial cells covering all abdominal organs and the abdominopelvic wall. Peritoneal metastases are formed after exfoliation of free tumor cells from a primary tumor invading the peritoneum. Consequently, most peritoneal metastases originate from abdominal organs such as the colon, rectum, stomach, or ovaria ...
H. J. Braam, F. J. H. Hoogwater
openaire   +2 more sources

Surgical Considerations in Intraperitoneal Chemotherapy

2000
Carcinoma of the ovary and peritoneum typically spreads in a diffuse, intra-abdominal fashion, often limited to the peritoneal cavity, and not metastasizing via hematogenous or lymphatic routes. The development of intraperitoneal (ip) chemotherapy sought to deliver extraordinarily high concentrations of cytotoxic agents into the peritoneal cavity, to ...
Donald Wiper, Alexander W. Kennedy
openaire   +2 more sources

Intraperitoneal chemotherapy for ovarian carcinoma.

Journal of Clinical Oncology, 1988
The first step in killing a tumor cell with a chemotherapeutic agent is to deliver the drug to the cell. Whether the cell is intrinsically sensitive or realtively resistant, the effect of the drug is proportional to the product of its concentration and the duration of exposure.
openaire   +3 more sources